New Data, Price Discount Finally Sways NICE On Janssen's Zytiga
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has at last recommended the use of Janssen's Zytiga (abiraterone) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) before chemotherapy, three months after initially rejecting its use on the publicly funded National Health Service, due to inadequate cost-effectiveness and efficacy data.